I am internationally recognized as an innovative, patient-focused and highly analytical healthcare leader and clinical scientist with extensive Research and Development experience. I have a proven history of successfully leading international public and private partnerships and non-profit organizations through critical advancements and progress of clinical trials and large observational cohorts. Adept at building and maintaining partnerships between Pharma, patients, academia and governments. Wide-ranging technical and scientific knowledge comprises molecular biology, immunology, application of digital technology and in vivo disease models (pre-clinical and clinical). I led the initial clinical development of GSK’s inhaled anti-muscarinic portfolio, currently available to patients as Umeclidinium bromide.

During my previous tenure as President and CEO of the COPD Foundation, I transformed and expanded the organization to focus its patient-centered strategy in COPD, bronchiectasis and NTM lung disease, including the formation of the Community Engagement Committee (CenCo), conception of the first ever World Bronchiectasis Day and the Oxygen360 research and advocacy program and initiated the formation of PIVOT (Patient-Inspired Validation of Outcome Tools) effort as chair of its Steering Committee. As the driver and leader of COPD360Net, the COPD Foundation’s digital health, medical devices, and therapeutics development accelerator network, I championed strategic partnerships between ENA Respiratory, Renovion, and Savana Med with the COPD Foundation.

As a scientific researcher, I authored 200+ peer-reviewed publications including highly cited ones ORCID ID 0000-0002-5275-8062.